Cisplatin-resistant lewis lung carcinoma cells possess increased level of VEGF secretion

Experimental Oncology

Volumn 25, Issue 4, 2003, Pages 260-265

  Solyanik, G I ^a   Pyaskovskaya, O N ^a   Garmanchouk, L V ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Cisplatin; Drug resistance; Lewis lung carcinoma; Metastasis; VEGF

Indexed keywords

CISPLATIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CARCINOMA CELL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; DRUG EFFECT; LUNG CARCINOMA; LUNG METASTASIS; MATHEMATICAL MODEL; MOUSE; NONHUMAN; TUMOR VOLUME; ANGIOGENESIS; ANIMAL EXPERIMENT; CONTROLLED STUDY; DYNAMICS; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG INJURY; PROTEIN SECRETION; TUMOR GROWTH;

EID: 0742305809     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Scappaticci F. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-27.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
3. Jimenez B, Volpert OV. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med 2001; 78: 663-72.
4. Volpert O, Luo W, Liu T-J, Estrera VT, Logothetis C, Lin S-H. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem 2002; 277: 35696-702.
5. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002; 98: 682-9.
6. Zogakis TG, Libutti SK. General aspects of antiangiogenesis and cancer therapy. Exp Opin Biol Ther 2001; 1: 253-75.
7. Eatock MM, Schatzlein A, Kaye SB. Tumor vasculature as target for anticancer therapy. Cancer Treat Rev 2000; 26: 191-204.
8. Browder T, Butterfield CE, Kra'ling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-86.
9. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27: 482-7.
10. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2002; 2: 727-39.
11. Avramis IA, Kwock R, Avramis VI. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res 2001; 21: 2281-6.
12. Kerbel RS. Growth dominance of the metastatic cancer cells: cellular and molecular aspects. Adv Cancer Res 1990; 55: 87-131.
13. Yakshibaeva YR, Pyaskovskaya ON, Solyanik GI, Chekhun VF. Decrease in migration capacity of Lewis lung carcinoma cells during tumor growth and metastasis. Exp Oncol 2002; 24: 155-6.
14. Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002; 24: 280-3.
15. Alistratov AV, Lisniyak IA, Yatsenko SM, Vinnitsky VB. The dependence of VEGF level from characteristics of 3LL carcinoma development in C57B16 mice. Exp Oncol 2002; 24: 64-8.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 1983; 65: 55-63.
17. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-101.
18. Zhang L, Yang N, Garcia JR, Mohamed A, Benencia F, Rubin SC, Allman D, Coukos G. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002; 161: 2295-309.
19. Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002; 99: 2179-84.
20. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001; 85: 273-8.
21. Theodorescu D, Cornil I, Sheehan C, Man S, Kerbel RS. Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. Int J Cancer 1991; 47: 118-23.
22. Solyanik GI, Bulkewicz RI, Kulik GI. One of the mechanisms of the metastatic cells dominance in heterogeneous tumor. Exp Oncol 1995; 17: 158.
23. Kolobov AV, Polezhaev AA, Solyanik GI. The role of cell motility in metastatic cell dominance phenomenon: analysis by mathematical model. J Theor Med 2000; 3: 63-77.
24. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 1999; 5: 783-9.
25. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 1999; 20: 177-81.
26. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003; 200: 183-94.